Compandia Touts Bioinformatics as Differentiator in Biomarker Discovery Market

The company was founded around 18 months ago with the goal of using artificial neural network technology to identify biomarkers in high-dimensional data sets generated by mass spectrometry, microarrays, next-generation sequencing, and other high-throughput experimental platforms.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.